Literature DB >> 7353343

The question of cumulation of digoxin metabolites in renal failure.

T P Gibson, H A Nelson.   

Abstract

Using high-performance liquid chromatography (HPLC) to separate digoxin from its metabolites digoxigenin, digoxigenin-bis-digitoxoside, and digoxigenin-mono-digitoxoside with subsequent quantitation by 125I radioimmunoassay (RIA), we examined the plasma of patients on long-term oral digoxin therapy. Digoxin was also measured by RIA without prior HPLC separation. Nine patients requiring maintenance dialysis and 9 subjects with lesser degrees of renal impairment were studied. Trace amounts of 1 or more of the digoxin metabolites were found in the plasma of all dialysis patients while subjects with lesser degrees of renal failure had either none or only 1 metabolite in trace amounts. The ratio of HPLC digoxin without HPLC was 0.83 +/- 0.12 (SD) in renal failure patients and 1.06 +/- 0.09 in subjects with renal function (p less than 0.01). RIA overestimates the amount of digoxin in plasma of renal failure patients and in them from 6% to 42% of plasma digoxin, as determined by conventional 125I RIA, may represent compounds other than digoxin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7353343     DOI: 10.1038/clpt.1980.34

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 2.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

3.  Evidence of nonlinearity in digoxin pharmacokinetics.

Authors:  J G Wagner; K D Popat; S K Das; E Sakmar; H Movahhed
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

Review 4.  Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations.

Authors:  A D Mooradian
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

5.  The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay.

Authors:  A F Cohen; R Kroon; H C Schoemaker; D D Breimer; A Van Vliet-Verbeek; H C Brandenburg
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 6.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

7.  Increased metabolism to dihydrodigoxin after intake of a microencapsulated formulation of digoxin.

Authors:  J O Magnusson; B Bergdahl; C Bogentoft; S Gustafsson; U E Jonsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.